335% Jump In 1 Yr: Multibagger Penny Stock Expands Global Footprint With Singapore Subsidiary Acquisition

Sudarshan Pharma Industries Limited (SPIL) has acquired 10,000 shares in Amar Ashok Vyas' pharmaceutical company for an estimated price of S$10,000. This acquires Sudarshan Singapore as an investment company branch, allowing SPIL to further widen their boundaries. This partnership, valued at Rs 635,500, further strengthens the claims SPIL has at an international scale.

For the fifth year in a row now SPIL has had an annual profit growth of 37% which adds to their recently acquired market cap of Rs 700 Crore. In a very recent development, SPIL's stock increased by 1.66%, thus rewarding shareholders with a Rs 33 value per share. During the past year, these figures have only increased, with SPIL rising 467% from their all-time low of Rs 5.82.

Sudarshan Pharma plans to allocate the revenue generated from the capital raise to working capital, expansion of the business, repayment of existing loans, and other corporate purposes. The last few reinvestments made have also resulted in stimulated growth and improved operational capability for the company, thus micromanaging the funds will further solidify their goals.

In November 2024, the corporation implemented a stock split by converting one equity stock with a nominal value of Rs 10 each into 10 equity stocks with a nominal value of Re 1 each. This increase in investor engagement and interest in the stock's performance can be attributed to improved liquidity.

Sudarshan Pharma Industries Limited, which was established in 2008 and is located in Mumbai, is one of the largest contract manufacturers of generic formulations. It serves institutions and healthcare facilities in several areas, like specialty chemicals, intermediates, Active Pharmaceutical Ingredients (APIs), pharmaceutical and formulation generics, as well as bulk supply.

Alongside contract manufacturing, the company expanded into branded products with Vimac Healthcare. Much of the product portfolio is registered with the "R" trademark, which indicates brand loyalty. SPIL works with well-known Indian companies and institutional clients in contract manufacturing for pharmaceutical formulation and medicines.

The Singapore subsidiary acquisition, together with strategic capital investment and differentiation enables Sudarshan Pharma Industries Limited to sustain its competitive advantage. The company is poised to consolidate its leadership position in the contract manufacturing industry due to its continuously increasing international presence and strong financial results.